

## DAFTAR PUSTAKA

- Allen, A., C. Fisher, A. Premawardhena, T. Peto, S. Allen, M. Arambepola, V. Thayalsutha, N. Olivieri, D. Weatherall. 2010. Adaptation to anemia in hemoglobin E- $\beta$  thalassemia. *Blood*, 116:5368-5370.
- Angelucci, E., S. Matthes-Martin, D. Baronciani, F. Bernaudin, S. Bonanomi, M.D. Capellini, J.H. Dalle, P.D. Bartolomeo, C.D. Heredia, R. Dickerhoff, C. Glardini, E. Glukman, A.A. Hussein, N. Kamani, M. Minkov, M. Cavazzana, C. Peters. 2014. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. *Hematologica*, 99(5): 811-820.
- Ansari, S.H., S. Tahir, S. Fahad, I. Muhammad, P. Kausar, F. Tasneem, P. Vinodh, Y. Ayesha, M. Tabassum. 2007. Efficacy of hydroksiurea in reduction of packed red cell transfusion requirement among children having beta-thalassemia major: Karachi HU Trial. *Journal of Pediatrics of Hematology Oncology*, 29(11): 743-746.
- Ansari, S., S.L. Zohra, M.A. Salima, O.A. Syed, S.S. Tahir. 2016. Hydroxyurea for  $\beta$ -thalassaemia major. *Cochrane Database of Systematic Reviews*, 1: 1-9.
- Asif, N., T. Anwar, H. Chaudary, K. Mehmood, N. Yaqoob, M. Tahir, K. Hassan. 2014. Treatment response to hydroxyurea in beta thalassemia. *Journal of Islamabad Medical & Dental College*, 3: 48-52.
- Banan, M. 2013. Hydroxyurea treatment in  $\beta$ -thalassemia patients: To respond or not to respond?. *Annals of Hematology*, 92: 289-299.
- Bailey, L., Y. Kuroyanagi, C.F. Franco-Penteado, N. Conran, S. Ausenda, M.D. Capellini, T. Ikuta. 2007. Expression of the  $\gamma$ -globin gene is sustained by the cAMP-dependent pathway in  $\beta$ -thalassaemia. *British Journal of Haematology*, 138(3): 382-395.
- Bayanzay, K. and R. Khan. 2015. Meta-analysis on effectiveness of hydroxyurea to treat transfusion-dependent beta-thalassemia. *Hematology*, 20: 469-476.
- Bayanzay, K., and L. Alzoebie. 2016. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. *Journal of Blood Medicine*, 7:159-169.
- Bradai, M., A. Mohand, P. Serge, L. Fatima, S. Laurent, D.M. Mariane. 2003. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. *Blood*, 102: 1529-1530.

- Bradai, M., S. Pissard, M.T. Abad, A. Dechartres, J.A. Ribeil, P. Landais, M. de Montalembert. 2007. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. *Transfusion*, 47(10):1830-1836.
- Bordbar, M.R., S. Samir, H. Sezaneh, K. Roza, B. Marzieh, K. Mehran. 2014. Hydroxyurea treatment in transfusion-dependent  $\beta$ -thalassemia patients. *Iran Red Crescent Medical Journal*, 16: 18-28.
- Borgna-Pignatti, C. and M.R. Gamberini. 2011. Complication of thalassemia major and their treatment. *Expert Review of Hematology*, 4(3): 353-366.
- Cappellini, M.D., A. Cohen, J. Porter, A. Taher, V. Viprakasit. 2014. Guidelines for the management of transfusion dependent thalassemia (TDT). *Thalassaemia International Federation*, 20: 42-98.
- Cappellini, M.D., C. Alan, E. Androulla, P. Antonio, P. John, T. Ali. 2008. Outline of diagnostic dilemmas in thalassaemia. In: *Guidelines for the clinical management of thalassaemia*. 2<sup>nd</sup> Revised edition. Nicosia (CY): Thalassaemia International Federation, 18.
- Choudhry, V., L. Amita, H.P. Pati, L.S. Arya. 1997. Hematological responses to hydroxyurea therapy in multitransfused thalassemic children. *Indian Journal of Pediatrics*, 64: 395-398.
- Chuncharunee, S., T. Sura, P. Winichagoon, S. Jindadamrongwech, P. Pootrakool, A. Bunyaratvej, S. Fuchareon. 2017. Effects of low dose hydroxyurea treatment on patients' quality of life in  $\beta$  thalassemia/hemoglobin E disease. *Journal of Hematology and Transfusion Medicine*, 27: 151-158.
- Crary, S.E. and G.R. Buchanan. 2009. Vascular complications after splenectomy for hematologic disorders. *Blood*, 114: 2861-2868.
- De, P., R. Mistry, C. Wright, S. Pancham, W. Burbridge, K. Gangopadhyay, T. Pang, G. Das. 2014. A review of endocrine disorders in thalassemia. *Open Journal Endocrinology and Metabolic Disease*, 4: 25-34.
- De Baun, M., F.J. Melissa, P.V. Elliot. 2016. Diseases of the blood, in: Kliegman. R., S. Bonita, St. J. Geme, N. Schor (Ed.). *Nelson Textbook of Pediatrics*. 20<sup>th</sup>. ed. Philadelphia: Elsevier. pp 2336–2345.
- De Sanctis V., C. Kattamis, D. Canatan, A.T. Soliman, H. Elsedfy, M. Karimi, S. Daar, Y. Wali, M. Yassin, N. Soliman, P. Sobti, S. Al Jaouni, M. El Kholy, B. Fiscina, M. Angastiniotis. 2017.  $\beta$ -thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. *Mediterranean Journal of Hematology and Infectious Disease*, 9(1): e2017018.

- Dhanya, R., R.K. Agarwal, A. Sedai, A. Kumari, L. Parmar, S. Hegde, Gayathri, A. Gowda, P. Gujjal, H. Pushpa, J.D. Ramaiah, C. Karri, S. Jali, N. Tallur, U.V. Shenoy, D. Pinto, S. Ramprakash, C.P. Raghuram, D. Trivedi, X. Cao, L. Faulkner. 2019. Assessment of mortality and its associated risk factors in patients with transfusion dependent thalassemia in India. *Blood*, 134 (Supplement\_1): 973.
- Dixit, A., T.C. Chatterjee, M. Pravas, M. Mahapatra, S. Tyagi, K. Madhulika, S. Renu, P.C. Ved. 2005. Hydroxyurea in thalassemia intermedia - A promising therapy. *Annals of Hematology*, 84: 441–446.
- Dzierzak, E. and S. Philipsen. 2013. Erythropoiesis: Development and differentiation. *Cold Spring Harbour Perspective Medicine*, 3: 1-16.
- Ehsani, M., A.H. Amir, B. Alireza, Z. Syrus, R. Armin. 2009. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. *Pediatric Hematology and Oncology*, 26: 560–565.
- Finotti, A., M. Borgatti, N. Bianchi, C. Zuccato, I. Lampronti, R. Gambari. 2016. Orphan drugs and potential novel approaches for therapies of  $\beta$ -thalassemia: Current status and future expectations. *Expert Opinion on Orphan Drugs*, 4(3): 299-315.
- Foong, W.C., J.J. Ho, C.K. Loh, V. Viprakasit. 2016. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.. *Cochrane Database of Systematic Reviews*, Issue 10. Art. No.: CD011579.
- Galanello, R. and R. Origa. Beta-thalassemia. 2010. *Orphanet Journal of Rare Disease*, 5: 11.
- Galanello, R., S. Sanna, L. Perseu, M.C. Sollaino, S. Satta, M.E. Lai, S. Barella, M. Uda, G. Usala, G.R. Abecasis, A. Cao. 2009 Amelioration of Sardinian  $\beta^0$  thalassemia by genetic modifiers. *Blood*, 114: 3935-3937.
- Ghasemi, A., B. Keikhaei, R. Ghodsi. 2014. Side effects of hydroxyurea in patients with thalassemia major and thalassemia intermedia and sickle cell anemia. *Iran Journal of Pediatrics Hematology Oncology*, 4: 114–117.
- Gibbon, R., D.R. Higgs, N.F. Olivieri, W.G. Wood. 2001. The beta-thalassaemias. In: D.J. Weatherall, J.B. Clegg (Ed.). *The thalassemia syndromes*. 4<sup>th</sup> ed. Blackwell Science. Oxford. 288-289.
- Gibbs, M.A., S.J. Sorensen. 2000. Hydroxyurea in the treatment of HIV-1. *Annals of Pharmacotherapy*, 34(1): 89-93.

- Gifford, S.C., J. Derganc, S.S. Shevkoplyas, T. Yoshida, M.W. Bitensky. 2006. A detailed study of time-dependent changes in human red blood cells: from reticulocyte maturation to erythrocyte senescence. *British Journal of Haematology*, 135: 395-404.
- Goldberg E.K., S. Neogi, A. Lal, A. Higa, E. Fung. 2018. Nutritional deficiencies are common in patients with transfusion-dependent thalassemia and associated with iron overload. *Journal of Food and Nutrition Research*. (Newark), 6(10): 674-681.
- Green, N. and S. Barral. 2014. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. *Pediatric research*, 75: 196–204.
- Gwilt, P.R. and W.G. Tracewell. 1998. Pharmacokinetics and pharmacodynamics of hydroxyurea. *Clinical Pharmacokinetics*, 34: 347–358.
- Hafeez, M., M. Aslam, A. Ali, Y. Rashid, M. Jafri. 2007. Regional and ethnic distribution of beta thalassemia mutations and effect of consanguinity in patients referred for prenatal diagnosis. *Journal of College of Physicians and Surgeons-Pakistan*, 17(3):144–147.
- Hall, J.E. 2011. Red blood cells, anemia, and polycythemia. In: *Guyton and Hall Textbook of Medical Physiology*. 12<sup>th</sup> Ed. Philadelphia: Elsevier. 413-422.
- Han-Ping, W., L. Cheng-Li, K. Yin-Chen, W. Kang-Hsi, L. Rouh-Lih, P. Ching-Tien, T. Weng, T. Yu-Man, C. Yu-Hua. 2017. Survival and complication rates in patients with thalassemia major in Taiwan. *Pediatric Blood and Cancer*, 64: 135-138.
- Hashemi, A., M. Abrishamkar, A.R. Jenabzade, Z. Eslami. 2009. Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. *Iranian Journal of Blood and Cancer*, 1(4):147–150.
- Hashemi, A., R. Ghilian, M. Golestan, G.M. Akhavan, Z. Zare, M.A. Dehghani. 2011. The study of growth in thalassemic patients and its correlation with serum ferritin level. *Iranian Journal of Pediatric Hematology Oncology*, 1(4): 147-151.
- Hassan, T, M. Badr, U. El Safy, M. Hesham, L. Sherief, M. Zakaria. 2016.  $\beta$  thalassemia: Genotypes and phenotypes, epidemiology of communicable and non-communicable diseases - Attributes of lifestyle and nature on humankind, Fyson H. Kasenga, IntechOpen, DOI: 10.5772/64644.
- Hoppe, C., V. Elliott, L. Bradley, F. Dru, S. Lori. 1999. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. *American Journal of Hematology*, 12(3):295-297.

- Ikuta, T., Y. Kuroyanagi, N. Odo, S. Liu. 2013. A common signaling pathway is activated in erythroid cells expressing high levels of fetal hemoglobin: a potential role for cAMP-elevating agents in  $\beta$ -globin disorders. *Journal of Blood Medicine*, 4: 149-159.
- Inati, A, M.H.A. Noureldine, A. Mansour, H.A. Abbas. 2015. Endocrine and bone complications in  $\beta$  thalassemia intermedia: current understanding and treatment. *BioMed Research International*, 2015: 813098.
- Italia K.Y., F.J. Jijina, R. Merchant, S. Panjwani, A.H. Nadkarni, P.M. Sawant, S.B. Nair, K. Ghosh, R.B. Colah. 2009. Response to hydroxyurea in  $\beta$  thalassemia major and intermedia: experience in western India. *Clinica Chimica Acta*, 407(1-2):10-15.
- Karimi, M. 2009. Hydroxyurea in the management of thalassemia intermedia. *Hemoglobin*, 33: 1-2.
- Karimi, M., C. Naden, M. Kazem, M.J. Falahi. 2010. Adverse effect of hydroxuyrea in  $\beta$ -thalassemia intermedia patients: 10 years experience. *Pediatric Hematology and Oncology*, 27:205-211.
- Karimi, M., H. Sezaneh, F. Ali, Y. Majid. 2012. Genotype-phenotype relationship of patients with beta-thalassemia taking hydroxyurea: a 13-year experience in Iran. *International Journal of Hematology*, 95: 51-56.
- Karunaratna, A.M.D.S., J.G.S. Ranasingha, R.M. Mudiyanse. 2018. Zinc Status in beta thalassemia major patients. *Biological Trace Element Research*, 184: 1-6.
- Keikhaei, B., H. Yousefi, M. Bahadoram. 2015. Clinical and haematological effects of hydroxyurea in  $\beta$ -Thalassemia intermedia patients. *Journal of Clinical and Diagnostic Research*, 9(10): 1-3.
- Kiani, R., M. Anwar, U. Waheed, M.J. Asad, S. Abbasi, H.A. Zaheer. 2016. Epidemiology of transfusion transmitted infection among patients with  $\beta$ -thalassaemia major. Pakistan. *Journal of Blood transfusion*, 2016: 8135649.
- Koc, A., W. Linda, M. Christopher, M. Gary. 2004. Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. *The Journal of biological chemistry*, 279: 223-30.
- Koren, A, L. Carina, D. Orly, T. Kransnov, E. Ronit, Z. Lucia, P. Haya, T. Hannah. 2008. Response to hydroxyurea therapy in  $\beta$  thalassemia. *American Journal of Hematology*, 83(5):366-370.
- Kosaryan, M., K. Vahidshahi, H. Karami, S. Ehteshami. 2009. Effect of hydroxyurea on thalassemia major and thalassemia intermedia in Iranian patients. *Pakistan Journal of Medical Science*, 25(1):74-78.

- Kosaryan, M., M. Zafari, A. Alipur, A. Hedayatizadeh-Omran. 2014. The effect and side effect of hydroxyurea therapy on patients with beta-thalassemia: A systematic review to December 2012. *Hemoglobin*, 38:262-271.
- Lee, S.H., P.R. Crocker, S. Westaby, N. Key, D.Y. Mason, S. Gordon, D.J. Weatherall. 1988. Isolation and immunocytochemical characterization of human bone marrow stromal macrophages in hemopoietic clusters. *Journal of Experimental Medicine*, 168:1193-1198.
- Leimberg, M.J., E. Prus, A.M. Konijn, E. Fibach. 2008. Macrophages function as a ferritiniron source for cultured human erythroid precursors. *Journal of Cellular Biochemistry*, 103: 1211-1218.
- Liu, R.R., M.Y. Wang, Y.R. Lai. 2010. Analysis of  $G\gamma$ -158(C>T) polymorphism in hemoglobin E/ $\beta$ -thalassemia major in Southern China. *Journal of Hematology Oncology*, 3:29.
- Mabaera, R., R.J. West, S.J. Conine, E.R. Macari, C.A. Engman, C.H. Lowrey. 2008. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. *Experimental Hematology*, 36(9):1057-1072.
- Mettananda, S., R.J. Gibbons, D.R. Higgs. 2015.  $\alpha$ -globin as a molecular target in the treatment of  $\beta$ -thalassemia. *Blood*, 125: 3694–3701.
- Mettananda, S., H. Pathiraja, R. Peiris, N. Wickramarathne, D. Bandara, U. Silva, C. Mettananda, A. Premawardhena. 2019. Blood transfusion therapy for  $\beta$ -thalassemia major and hemoglobin E  $\beta$ -thalassemia: Adequacy, trends, and determinants in SriLanka. *Pediatrics Blood & Cancer*, e27643.
- Mohtasham-Amiri, Z., K. Khanaki, A. Davoudi-Kiakalayeh, S.M. Rezvani, A. Jafari-Shakib, R. Jafari-Shakib. 2018. Analysis of Survival in Patients with  $\beta$ -thalassemia major in Guilan, Northern Iran. *Iranian Journal of Blood and Cancer*, 10(3): 82-86.
- Moirangthem, A. and S.R. Phadke. 2018. Socio-demographic profile and economic burden of treatment of transfusion dependent thalassemia. *Indian Journal Pediatrics*, 85: 102.
- Musallam, K.M., V.G. Sankaran, M.D. Cappellini, L. Duca, D.G. Nathan, A.T. Taher. 2012. Fetal hemoglobin levels and morbidity in untransfused patients with  $\beta$ -thalassemia intermedia. *Blood*, 119(2): 364-347.
- Najafipour, F., A. Aliasgarzadeh, M. Niafar, M. Mobaseri, N. Aghamohamadzadeh, R.S. Sorkhabi. 2008. Evaluation of glucose metabolism, thyroid function, growth and development pattern and calcium status in patients with thalassemia major. *Research Journal of Biological Science*, 3: 867-873.

- Neishabury, M., A. Azarkeivan, H. Najmabadi. 2010. Frequency of positive XmnI  $G\gamma$  polymorphism and coinheritance of common alpha thalassemia mutations do not show statistically significantly difference between thalassemia major and intermedia cases with homozygous IVSII-1 mutation. *Blood Cells, Molecules Diseases*, 44: 95-99.
- Nuntakarn, L., S. Fucharoen, G. Fucharoen, K. Sanchaisuriya, A. Jetsrisuparb, S. Wiangnon. 2009. Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E/ $\beta$ -thalassemia in Northeast Thailand. *Blood Cells, Molecules Diseases*, 42: 32-35.
- Olivieri, N.F., G.M. Muraca, A. O'Donnell, A. Premawardhena, C. Fisher, D.J. Weatherall. 2008. Studies in hemoglobin E/ $\beta$ -thalassemia. *British Journal of Hematology*, 141: 388-397.
- Orah, S. 2008. Hydroxyurea for the treatment of sickle cell disease. *The New English Journal of Medicine*, 358: 1362-1369.
- Orkin, S.H. 2000. Diversification of haematopoietic stem cells to specific lineages. *Nature Reviews Genetics*, 1: 57-64.
- Panepinto, J.A., R.C. Punzalan, S.J. Paul. 2014. Section 20 Hematology. In: Marcdante, K.J., R.M. Kliegman, (Ed.). *NELSON Essentials of Pediatrics*, Philadelphia: Elsevier: 509–523.
- Patel, S., P. Purohit, R.S. Mashon, S. Dehury, S. Meher, S. Sahoo, S.S. Dash, K. Das, D.K. Patel. 2014. The effect of hydroxyurea on compound heterozygotes for sickle cell-haemoglobin. D-Punjab--a single centre experience in eastern India. *Pediatric Blood & Cancer*, 61(8):1341-1346.
- Pemde, H., J. Chandra, D. Gupta, V. Singh, R. Sharma, A. Dutta. 2011. Physical growth in children with transfusion-dependent thalassemia. *Pediatric Health, Medicine and Therapeutics*, 2: 2-13.
- Porter, J. and V. Viprakasit. 2014. Iron overload and chelation, in Cappellini, M. and A. Cohen (ed.). *Guidelines for the management of transfusion dependent thalassaemia (TDT)*. 3<sup>rd</sup> edition. Milan: Thalassaemia International Federation, Nicosia (CY), pp. 1–35.
- Pourfarzad, F., M. von Lindern, A. Azarkeivan, J. Hou, K.S. Kheradmand, F. Esteghamat, W. van Ijcken, S. Philipsen, H. Najmabadi, F. Grosveld. 2013. Hydroxyurea responsiveness in  $\beta$ -thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. *Haematologica*. 98(5): 696-704.

- Ravangard, R., Z. Mirzaei, K. Keshavarz, S. Haghpanah, M. Karimi. 2017. Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost effectiveness study. *Hematology*, 23(7): 417-422.
- Rashidighader, F. M. Kosaryan, D. Farzin. 2007. High dose deferoxamine treatment (intravenous) for thalassemia patients with cardiac complications. *East Mediterr. Health Journal*, 13(5): 1053-1059.
- Rees, D.C., D. Weatherall, J.B. Clegg, J.B. Porter. 1999. Why are hemoglobin F levels increased in HbE/  $\beta$ -thalassemia. *Blood*, 94:3199-3204.
- Rekam Medik RS Dr. Soetomo Surabaya. 2015. Data pasien talasemia di poli rawat jalan hematologi onkologi anak RS Dr Soetomo. Surabaya.
- Rekam Medik RS Dr. Soetomo Surabaya. 2018. Data pasien talasemia di poli rawat jalan hematologi onkologi anak RS Dr Soetomo. Surabaya.
- Ribeil, J.A., J.B. Arlet, M. Dussiot, I.C. Moura, G. Courtois, H. Olivier. 2013. Ineffective erythropoiesis in  $\beta$ -thalassemia. *Scientific World Journal*, 1-11.
- Rund, D. and E. Rachmilewitz. 2005.  $\beta$  -Thalassemia. *New England Journal of Medicine*, 353: 1135–1146.
- Saki, N., S. Abroun, M. Soleimani, M. Kavianpour, M. Shahjahani, J. Mohammadi-Asl, S. Hajizamami. 2016. MicroRNA expression in  $\beta$ -thalassemia and sickle cell disease: a role in the induction of fetal hemoglobin. *Cell Journal*, 17: 583–592.
- Schier, S., C. Filippo, V. Michael, L. Ma, A. Emanuele. 2003. The role of oxidant injury in the pathophysiology of human thalassemias. *Redox Report*, 8: 241–245.
- Schmidt, C.W.P. 2019. Pharmacokinetics and pharmacodynamics of chemotherapy in children: The most used drugs. *Pediatric Oncologic Pharmacy*, 41-65.
- Schrier, S. and D. Mahoney. 2016. Pathophysiology of beta thalassemia. Up to date medicine. Available:<https://www.uptodate.com/contents/pathophysiology-of-beta-thalassemia>
- Segal, J., J. Strouse, M. Beach, C. Haywood, C. Witkop, H. Park, R.F. Wilson, S. Lanzkron. 2008. Hydroxyurea for the treatment of sickle cell disease. *Evidence Report/Technology Assessments*, 165:1-95.
- Sheikh, M.A., M.U. Shakir, M. Shah. 2017. The assessment of nutritional status of children with beta thalassemia major with body mass index. *Pakistan Journal of Medical and Health Sciences*, 11(1): 262-265.



- Soliman, A., and V.D. Sanctis. 2013. Growth disorders in thalassemia. The Ludhiana Booklet. Growth disorders and endocrine complications in thalassaemia. 11.
- Spanos, T., M. Karageorga, V. Ladis, J. Peristeri, A. Hatziliami, C. Kattamis. 1990. Red cell alloantibodies in patients with thalassemia. *Vox Sanguinis*, 58:50-55.
- Sripichai, O., and S. Fucharoen. 2016. Fetal hemoglobin regulation in  $\beta$ -thalassemia: heterogeneity, modifiers and therapeutic approaches. *Expert Review of Hematology*, 9:12, 1129-1137.
- Sripichai, O., C.M. Kiefer, N.V. Bhanu, T. Tanno, N. Seung-Jae, G. Sung-Ho, J.E. Russell, C.L. Rognerud, O. Ching-Nan, P.A. Oneal, E.R. Meier, N.M. Gantt, C. Byrnes, Y.T. Lee, A. Dean, and J.L. Miller. 2009. Cytokine-mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming. *Blood*, 114(11): 2299-2306.
- Srivastava, A, and R.V. Shaji. 2017. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy. *Hematologica*, 102(2): 214-223.
- Steinberg, M., W.F. McCarthy, O. Castro, S.K. Ballas, F.D. Armstrong, W. Smith, K. Ataga, P. Swerdlow, A. Kutlar, L. DeCastro, M.A. Waclawiw. 2011. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. *American Journal of Hematology*, 85: 403–408.
- Stone, R. 2004. Optimizing treatment of chronic myeloid leukemia: a rational approach. *The Oncologist*, 9: 259–270.
- Strouse, J. and M. Beach. 2008. Hydroxyurea for the treatment of sickle cell disease. Rockville: agency for healthcare research and quality, 1-4.
- Taher, A.T., K.M. Musallam, M.D. Cappellini, D.J. Weatherall. 2011. Optimal management of beta thalassaemia intermedia. *British Journal of Haematology*, **152**: 512-523.
- Taher, A.T., E. Vichinsky, K. Musallam, M. Capellini, V. Viprakasit. 2013. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). TIF publication, 19: 84-91.
- Taher, A.T., and A.N. Saliba. 2017. Iron overload in thalassemia: different organs at different rates. *Hematology*. American Society of Hematology. Education Program. 1: 265–271.
- Thein, S.L. 2004. Genetic insights into the clinical diversity of  $\beta$ -thalassemia. *British Journal of Haematology*, 124:264-274.

- Thein, S.L. 2008. Genetic modifiers of the  $\beta$ -hemoglobinopathies. *British Journal of Haematology*, 141:357-366.
- Thein, S.L., and S. Menzel. 2009. Discovering the genetics underlying foetal hemoglobin production in adults. *British Journal of Haematology*, 141:357-366.
- Thein, S.L., S. Menzel, X. Peng, S. Best, J. Jiang, J. Close, N. Silver, A. Gerovasilli, C. Ping, M. Yamaguchi, K. Wahlberg, P. Ulug, T.D. Spector, C. Garner, F. Matsuda, M. Farrall, M. Lathrop. 2007. Intergenic variants of HBS1 L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. *Proceedings of the National Academy of Sciences of the United States of America*, 104: 11346-113451.
- Thein, S. 2013. The molecular basis of  $\beta$ -thalassemia. *Cold Spring Harbour. Perspective Medicine*, 3(5): 1–24.
- Tiosano, D. and Z. Hochberg. 2001. Endocrine complications of thalassemia. *Journal of Endocrinological Investigation*, 24: 716-723.
- Tsai, M., K. Ashley, L. Joseph, R. Ross, N.H. James, M. Joel, W. Russell, A.F. Daniel, A.L. Wilbur. 2012. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic disease using microfluidic technology. *Journal of Clinical Investigation*, 122: 408–418.
- Vichinsky, E., L. Neumayr, S. Trimble, P.J. Giardina, A.R. Cohen, T. Coates, J. Boudreaux, E.J. Neufeld, K. Kenney, A. grant, A.A. Thompson. 2015. Transfusion complications in thalassemia patients: a report from the centers for disease control and prevention (CDC). *Transfusion*, 54(4): 971-972.
- Viprakasit, V., R. Origa, S. Fucharoen. 2014. Genetic basis, pathophysiology and diagnosis the thalassaemias: definitions and worldwide distribution. In: Cappellini, M. and A. Cohen (Ed.). *Guidelines for the management of transfusion dependent thalassaemia (TDT)*. 3<sup>rd</sup>. ed. Milan: Thalassaemia International Federation, Nicosia (CY): 1–10.
- Ware, R.E. 2010. How i treat how i use hydroxyurea to treat young patients with sickle cell anemia. *Cell*, 115: 5300–5311.
- Ware, R.E., B. Eggleston, R. Redding-Lallinger, W.C. Wang, K. Smith-Whitley, C. Daeschner, B. Gee, L.A. Styles, R.W. Helms, T.R. Kinney, and K. Ohene-Frempong. 2002. Predictors of fetal hemoglobin response in children with sickle cell anemiareceiving hydroxyurea therapy. *Blood*, 99: 10-14.
- Weatherall, D.J. 2001. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. *Nature Reviews Genetics*, 2: 245–255.

- Xu, J., D.E Bauer, S.H Orkin. 2011. Targeting regulators of hemoglobin f. *Hematology*, 8: 1–7.
- Yadav, A., P. Abrol, S. Singh, M. Singh, S. Nanda. 2016. Hydroxyurea in thalassemia major. *Journal of Evolution of Medical and Dental Sciences*, 5(5):287-291.
- Yaman, A., P. Isik, N. Yarali, S. Karademir, S. Cetinkaya, A. Bay, S. Ozkasap, A. Kara, B. Tunc. 2013. Common complications in beta-thalassemia patients. *International Journal of Hematology and Oncology*, 23: 193-199.
- Yanpanitch, O., S. Hatairaktham, I. Charoensakdi. 2015. Treatment of  $\beta$ -thalassemia / hemoglobin E with antioxidant cocktails results in decreased oxidative stress, increased hemoglobin concentration, and improvement of the hypercoagulable state. *Oxidative Medicine and Cellular Longevity*. Hindawi Publishing Corporation. 1–8.
- Yarbro, J. 1992. Mechanism of action of hydroxyurea. *Seminars in oncology*, 19: 1–10.
- Yavarian, M., M. Karimi, E. Bakker, C. Harteveld, P. Giordano. 2004. Response to hydroxyurea treatment in Iranian transfusion-dependent  $\beta$ -thalassemia patients. *Haematologica*, 89: 1172-1178.
- Younis, M.A. 2017. Evaluation of Serum Ferritin, Creatinine and Liver Enzymes in Patients with  $\beta$ -thalassemia After Administration of Deferasirox. *Tikret Journal of Pharmaceutical Sciences*, 12(1), 68-75.
- Yu, X., Y. Kong, L.C. Dore, O. Abdulmalik, A.M. Katein, S. Zhou, J.K. Choi, J.P. Mackay, A.J. Gow, M.J. Weiss. 2007. An erythroid chaperone that facilitates folding of  $\alpha$ -globin subunits for hemoglobin synthesis. *Journal of Clinical Investigation*, 117: 1856–1865.
- Zamani, F., R. Shakeri, S.M. Eslami, S.M. Razavi, A. Basi. 2009. Hydroxyurea therapy in 49 patients with major beta-thalassemia. *Archives of Iranian Medicine*, 12: 295-297.
- Zimmerman, S.A., W.H. Schultz, J.S. Davis, C.V. Pickens, N.A. Mortier, T.A. Howard, and R.E. Ware. 2004. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. *Blood*, 103: 2039-2045.
- Zivot, A., J.M. Lipton, A. Narla, L. Blanc. 2018. Erythropoiesis: insights into pathophysiology and treatments in 2017. *Molecular Medicine*, 24: 11.